Member, Molecular Oncology and Biomarkers
Associate Professor, Biochemistry and Molecular Biology
Associate Professor, Graduate Studies
Molecular Oncology & Biomarkers ProgramGeorgia Cancer Center 1410 Laney Walker Blvd. Office: CN-1161 Desk: (706) 721-4219
The main focus of Dr. Muthusamy Thangaraju’s (Raju) laboratory is to identify the functional implication of DNA methyl transferases (DNMTs), histone methyl transferases (HMTs), and histone dimethyl trasferases (HDACs) in regulation of mammary stem/progenitor and cancer stem cells. This laboratory is also involved in understanding the functional significance of mammary gland remodeling in regulation of multi-pregnancies associated breast cancer prevention. The following key projects are undergoing in my laboratory.
Role of DNA methyltransferase 1 (DNMT1) in regulation of mammary stem/progenitor and cancer stem cells: Mammary stem/progenitor cells (MaSCs) maintain self-renewal of the mammary epithelium during puberty and pregnancy. DNA methylation provides a potential epigenetic mechanism for maintaining cellular memory during self-renewal. Although DNA methyltransferases (DNMTs) are dispensable for embryonic stem cell maintenance, their role in maintaining MaSCs and cancer stem cells (CSCs) in constantly replenishing mammary epithelium is unclear. The Thangaraju laboratory has recently shown that DNMT1 is indispensable for MaSC maintenance. Furthermore, they found that DNMT1 expression is elevated in mammary tumors, and mammary gland-specific DNMT1deletion protects mice from mammary tumorigenesis by limiting the CSC pool. Through genome-scale methylation studies, they identified ISL1 as a direct DNMT1 target, hypermethylated and downregulated in mammary tumors and CSCs. DNMT inhibition or ISL1 expression in breast cancer cells limits CSC population. Altogether, these studies uncover an essential role for DNMT1 in MaSC and CSC maintenance and identify the DNMT1-ISL1 axis as a potential therapeutic target for breast cancer treatment. This laboratory also identified a small molecule inhibitor that inhibits DNMT1 along with inhibition of histone methyltransferases (HMTs), like DOT1L, MLL1, NSD1, and SETD2. In addition, this small molecule inhibitor prevents breast cancer by blocking breast cancer stem cells, specifically basal myoepithelial stem cells. They are evaluating the therapeutic potential of this drug for breast cancer prevention and treatment.
The Thangaraju laboratory is also evaluating the role of the G-protein coupled receptor 109A (GPR109A), Niacin and Butyrate receptor, and membrane transporter SLC5A8, a butyrate receptor, in mammary gland remodeling and their relevance to breast cancer prevention and treatment. In addition, this laboratory is evaluating the functional implication of silent information regulator 1 (SIRT1) in the regulation of mammary gland development and its role in mammary tumor growth and progression. Some of the important projects ongoing and/or of interest in the group are:
Ramachandran S, Elangovan S, Pathania P, Ananth S, Gnana-Prakasam J, Fulzele S, Wenger KH, Pawar S, Sterneck E, Boettger T, Prasad PD, Smith SB, Ganapathy V, Thangaraju M. (2015) Disruption of SLC5A8 promotes mammary tumor growth and progression. (Under revision in Developmental Cell).
Pathania P, Ramachandran S, Elangovan S, Padia R, Yang P, Cinghu S, Veeranan-Karmegam R, Arjunan P, Gnana-Prakasam J, Fulzele S, Pei L, Chang C-S, Choi J-H, Shi H, Manicassamy S, Prasad PD, Sharma S, Ganapathy V, Jothi R, Thangaraju M. (2015) DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis. Nature Comm. (In press)
Elangovan S, Pathania R, Ramachandran S, Ananth S, Padia RN, Lan L, Singh N, Martin PM, Hawthorn L, Prasad PD, Ganapathy V, Thangaraju M. (2014) The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.Cancer Res. 74:1166-78.
Elangovan S, Pathania R, Ramachandran S, Ananth S, Padia RN, Hawthorn L, Schoenlein PV, Boettger T, Smith SB, Prasad PD, Ganapathy V, Thangaraju M.(2013) SLC5A8 functions as a tumor suppressor in mammary gland and is silenced in breast cancer by HRAS-induced DNMT1. Mol Cell Biol. 33:3920-35. (Spotlight Article)
Elangovan S, Ramachandran S, Venkatesan N, Ananth S, Gnana-Prakasam J, Martin PM, Browning DD, Schoenlein PV, Prasad PD, Ganapathy V, Thangaraju, M. (2011) SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor-α in breast cancer. Cancer Res. 71:6654-64.
Babu E, Ramachandran S, CoothanKandaswamy V, Elangovan S, Prasad PD, Ganapathy V, Thangaraju M. (2011) Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate. Oncogene. 30:4026-37.
Thangaraju M,Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD, Ganapathy V. (2009) Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer. 115:4655-66.
Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, Mellinger JD, Smith SB, Digby GJ, Lambert NAPrasad PD, Ganapathy, V. (2009) GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res.69: 2826-32.
Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD, Sterneck E, Ganapathy V. (2006) SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 66:11560-4.
Thangaraju M, Ananth S, Martin PM, Roon P, Smith SB, Sterneck E, Prasad PD, Ganapathy V. (2006) c/ebpdelta Null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney.J Biol Chem.281:26769-73.
Thangaraju M, Rudelius M, Bierie B, Raffeld M, Sharan S, Hennighausen L, Huang AM, Sterneck E. (2005) C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development.132:4675-85.